Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007
One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism Source: Annual Congress 2003 - Pulmonary hypertension Year: 2003
Pulmonary embolism and pregnancy Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177 Year: 2004
Early discharge of patients with pulmonary embolism: a two-phase observational study Source: Eur Respir J 2007; 30: 708-714 Year: 2007
Possible anti-inflammatory activity of low molecular weight heparin in patients with high risk of pulmonary embolism Source: Eur Respir J 2004; 24: Suppl. 48, 684s Year: 2004
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Internal validation of a model to predict the risk of short-term (10 days) adverse outcomes in patients with pulmonary embolism (PE) Source: Annual Congress 2006 - Pulmonary embolism Year: 2006
A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE) Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Preliminary results of a multicenter study for home treatment of pulmonary embolism (PE) Source: Eur Respir J 2006; 28: Suppl. 50, 365s Year: 2006
Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001
Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019
Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001
Massive and sub-massive pulmonary embolism (PE) long-term follow up data: Is there a need for dedicated PE clinics? Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018
Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015
Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review Source: Eur Respir J 2009; 33: 1148-1155 Year: 2009
1 year clinical follow-up of patients affected by acute pulmonary embolism (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 270s Year: 2005